EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-world Gastrointestinal, Pancreaticobiliary, Cardiorenal, Metabolic and Nutritional Outcomes of GLP-1 or GIP Receptors Agonists -based Therapy in Chronic Pancreatitis

Arkadeep Dhali, Rick Maity, Fayaz Khan

Journal of Gastrointestinal and Liver Diseases · 21.11.2026

DOI: 10.15403/jgld-6964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, online erschienen am 21.11.2026. Verfasst von Arkadeep Dhali und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Glucagon-like peptide-1(GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists are increasingly used for metabolic disease, but their safety profile in patients with chronic pancreatitis (CP) remains uncertain. We compared several gastrointestinal, cardio, renal and metabolic outcomes in patients with CP exposed to dulaglutide, semaglutide, or tirzepatide versus propensity-matched unexposed controls.

Methods

We conducted a retrospective, propensity score-matched cohort study using the TriNetX federated real-world data platform. Adults with CP were classified by recorded exposure to dulaglutide, semaglutide, or tirzepatide versus no recorded exposure to those drugs. Risk analyses and Kaplan-Meier time-to-event analyses were done.

Results

After matching, median follow-up was 588 (IQR 831) versus 879 (IQR 807), respectively. Nausea/vomiting occurred in 656/4,938 (risk 0.133) versus 1,099/5,585 (risk 0.197), with risk ratio (RR) 0.675 (95%CI: 0.618-0.738) and hazard ratio (HR) 0.710 (95%CI: 0.645-0.783). Bowel obstruction/ileus occurred in 241/9,103 (risk 0.026) versus 466/8,949 (risk 0.052), with RR=0.508 (95%CI: 0.436-0.592) and HR=0.556 (95%CI: 0.476-0.649). Upper gastrointestinal bleeding occurred in 355/8,536 (risk 0.042) versus 608/8,657 (risk 0.070), with RR=0.592 (95%CI: 0.521-0.673) and HR=0.659 (95%CI: 0.578-0.751). Biliary/procedural outcomes were lower, including cholecystectomy (risk 0.023 vs 0.049; HR=0.486, 95%CI: 0.412-0.572) and ERCP (risk 0.026 vs 0.064; HR=0.420, 95%CI: 0.362-0.488). Recurrent acute pancreatitis occurred in 329/5,639 exposed patients (risk 0.058) versus 579/5,499 controls (risk 0.105), with HR=0.584 (95%CI: 0.510-0.669). Additional associations included lower insulin initiation (risk 0.178 vs 0.269; HR=0.731, 95%CI: 0.658-0.812), heart failure (risk 0.061 vs 0.101; HR=0.687, 95%CI: 0.613-0.770), myocardial infarction (risk 0.039 vs 0.054; HR=0.818, 95%CI: 0.712-0.939 and acute kidney injury (risk 0.086 vs 0.150; HR=0.643, 95%CI: 0.580-0.712), malnutrition (risk 0.049 vs 0.107; HR=0.491, 95%CI: 0.438-0.550).

Conclusions

Exposure to dulaglutide, semaglutide, or tirzepatide was associated with lower recorded risks across several gastrointestinal, cardio, renal and metabolic outcome domains. These findings should be interpreted with caution, and further prospective studies are required to confirm the same.

Zitieren

APA

Dhali, A., Maity, R., & Khan, F. (2026). Real-world Gastrointestinal, Pancreaticobiliary, Cardiorenal, Metabolic and Nutritional Outcomes of GLP-1 or GIP Receptors Agonists -based Therapy in Chronic Pancreatitis. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-6964

Vancouver

Dhali A, Maity R, Khan F. Real-world Gastrointestinal, Pancreaticobiliary, Cardiorenal, Metabolic and Nutritional Outcomes of GLP-1 or GIP Receptors Agonists -based Therapy in Chronic Pancreatitis. Journal of Gastrointestinal and Liver Diseases. 2026. doi:10.15403/jgld-6964

BibTeX
@article{Dhali2026,
  author = {Dhali, Arkadeep and Maity, Rick and Khan, Fayaz},
  title = {Real-world Gastrointestinal, Pancreaticobiliary, Cardiorenal, Metabolic and Nutritional Outcomes of GLP-1 or GIP Receptors Agonists -based Therapy in Chronic Pancreatitis},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2026},
  doi = {10.15403/jgld-6964}
}
Kostenlos starten →